Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients

Oncology Reports

Volumn 18, Issue 4, 2007, Pages 867-871

  Hoshino, Isamu ^a   Matsubara, Hisahiro ^a   Akutsu, Yasunori ^a   Nishimori, Takanori ^a   Yoneyama, Yasuo ^a   Murakami, Kentaro ^a   Sakata, Haruhito ^a   Matsushita, Kazuyuki ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Esophageal squamous cell carcinoma; Prdx1; Tumor suppressor

Indexed keywords

PEROXIREDOXIN; PRDX1 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEROXIREDOXINS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 38449096059     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.4.867     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Kurehara H, Ishiguro H, Kimura M, et al: A novel gene, RSRC2, inhibits cell proliferation and affects survival in esophageal cancer patients. Int J Oncol 30: 421-428, 2007.
3. Miller JD, Jain MK, de Gara CJ, Morgan D and Urschel JD: Effect of surgical experience on results of esophagectomy for esophageal carcinoma. J Surg Oncol 65: 20-21, 1997. (Pubitemid 27233051)
4. Wen ST and Van Etten RA: The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11: 2456-2467, 1997.
5. Mu ZM, Yin XY and Prochownik EV: Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 277: 43175-43184, 2002. (Pubitemid 35285703)
6. Neumann CA, Krause DS, Carman CV, et al: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565, 2003. (Pubitemid 36975778)
7. Hoshino I, Matsubara H, Hanari N, et al: Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 11: 7945-7952, 2005. (Pubitemid 41611642)
8. Villar-Garea A and Esteller M: Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112: 171-178, 2004. (Pubitemid 39244355)
9. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001. (Pubitemid 33741894)
10. Egger G, Liang G, Aparicio A, et al: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463, 2004. (Pubitemid 38715140)
11. Yanagawa T, Ishikawa T, Ishii T, et al: Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 145: 127-132, 1999. (Pubitemid 29459080)
12. Yanagawa T, Iwasa S, Ishii T, et al: Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 156: 27-35, 2000. (Pubitemid 30326764)
13. Quan C, Cha EJ, Lee HL, Han KH, Lee KM and Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 175: 1512-1516, 2006.
14. Odreman F, Vindigni M, Gonzales ML, et al: Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 4: 698-708, 2005. (Pubitemid 40863258)
15. Park JH, Kim YS, Lee HL, et al: Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11: 269-275, 2006.
16. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
17. Rhee SG, Chae HZ and Kim K: Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
18. Wood ZA, Poole LB and Karplus PA: Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300: 650-653, 2003. (Pubitemid 36520591)
19. Egler RA, Fernandes E, Rothermund K, Sereika S, de Souza-Pinto N, Jaruga P, Dizdaroglu M and Prochownik EV: Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 24: 8038-8050, 2005. (Pubitemid 41746747)
20. Prosperi MT, Ferbus D, Karczinski I and Goubin G: A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem 268: 11050-11056, 1993. (Pubitemid 23162291)
21. Zhang B, Su Y, Ai G, Wang Y, Wang T and Wang F: Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J Radiat Res 46: 305-312, 2005. (Pubitemid 43086300)
22. Gisin J, Perren A, Bawohl M and Jochum W: Rare allelic imbalances, but no mutations of the PRDX1 gene in human hepatocellular carcinomas. J Clin Pathol 58: 1229-1231, 2005. (Pubitemid 41566476)